Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024 and so far in 2025, driven by ...

Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has ...

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...